Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Apr 2, 2025
Product Development
VEGF bispecifics make inroads in other cancers, and more: Clinical Report
Plus: The week’s gainers and decliners after data
BioCentury | Apr 1, 2025
Product Development
Oral PCSK9 inhibition: Will co-formulation drive success?
AZ’s latest data position AZD0780 as slightly less effective but more convenient than PCSK9 competition
BioCentury | Mar 12, 2025
Discovery & Translation
Science Spotlight: Killing the mesenchymal precursors that drive cancer progression
BioCentury’s roundup of translational innovations also includes blood detection of pregnancy complications, BBB-crossing antibodies, and more
BioCentury | Feb 21, 2025
Editor's Commentary
No causal biology without diversity: a Perspective
As human data are poised to deliver causal targets and more precise interventions, caving to anti-DEI rhetoric
BioCentury | Feb 12, 2025
Deals
Antithrombotic comes back to Novartis via deal for Blackstone-backed Anthos
Pharma had held minority stake in 2019 spinout of mAb, now in Phase III for atrial fibrillation and cancer-associated thrombosis
BioCentury | Jan 18, 2025
Product Development
2025 catalysts: New modality showdowns
Genetic therapies compete in the same indications, as degraders come of age
BioCentury | Oct 9, 2024
Product Development
How to establish causality via patient observation
Strategies to find targets in patient data are largely grounded in genetics, but the toolbox is diversifying, and increasingly longitudinal
BioCentury | Oct 7, 2024
Deals
AstraZeneca, Hong Kong-based CSPC in deal for dyslipidemia therapy
Deals report: Recordati acquires Enjaymo from Sanofi, and updates from BioMarin-Camp4, Editas-DRI and more
BioCentury | Oct 7, 2024
Discovery & Translation
Causal biology in the age of big data
Where do you start? Patient data might sound more obvious, but human cell-based models have advantages
Items per page:
1 - 10 of 590